Mombaerts I, Koornneef L
Department of Ophthalmology, University of Amsterdam, The Netherlands.
Ophthalmology. 1997 Mar;104(3):402-8. doi: 10.1016/s0161-6420(97)30301-7.
Orbital myositis is described as exquisitely sensitive to therapy with systemic corticosteroids. However, it may turn into a recurrent or chronic disease, requiring repeated courses or maintenance of corticotherapy that often is complicated with serious side effects. The authors conducted this study to evaluate their experience and the current status in the literature as to treatment of orbital myositis with corticosteroids and corticosteroid-sparing alternatives.
The clinical records and computed tomography scans of patients with orbital myositis who presented at the Orbital Center Amsterdam between 1977 and 1991 were studied for the clinical course and therapeutic outcome. Recurrences were defined as a new attack of the same or another extraocular muscle as the primary affected, in the same or the other orbit.
The study group comprised 16 patients. All patients responded to initial treatment with oral corticosteroids (14/16) or nonsteroidal anti-inflammatory drugs (NSAID) (2/16). Of these 16 patients, 9 (56%) had 1 or more recurrences. Recurrences responded to repeated courses of corticosteroids, NSAID, or 20 Gy irradiation. Despite radiotherapy in six patients, recurrences continued to occur within a mean period of 2.7 years (range, 0.5 month-8.8 years). The mean follow-up after initial therapy in general was 9.7 years (range, 2.6-16.9 years), and after radiotherapy, in particular, was 7.4 years (range, 4.1-10.5 years).
Orbital myositis responds well to oral corticosteroids, but recurs in 50% of the cases. Based on a long-term follow-up of six patients who received irradiation of 20 Gy, radiotherapy appears ineffective in stopping recurrent orbital myositis.
眼眶肌炎被认为对全身皮质类固醇治疗极为敏感。然而,它可能会转变为复发性或慢性疾病,需要反复疗程或维持皮质类固醇治疗,而这常常伴有严重的副作用。作者开展本研究以评估他们在使用皮质类固醇及皮质类固醇替代疗法治疗眼眶肌炎方面的经验及当前文献中的现状。
对1977年至1991年间在阿姆斯特丹眼眶中心就诊的眼眶肌炎患者的临床记录和计算机断层扫描进行研究,以了解其临床病程和治疗结果。复发被定义为在同一或另一眼眶中,与原发性受累眼外肌相同或另一眼外肌出现新的发作。
研究组包括16例患者。所有患者对初始治疗均有反应,其中14例(14/16)使用口服皮质类固醇,2例(2/16)使用非甾体抗炎药(NSAID)。在这16例患者中,9例(56%)有1次或更多次复发。复发对重复疗程的皮质类固醇、NSAID或20 Gy放疗有反应。尽管6例患者接受了放疗,但复发仍在平均2.7年(范围0.5个月至8.8年)内持续发生。初始治疗后的平均随访时间总体为9.7年(范围2.6至16.9年),特别是放疗后的平均随访时间为7.4年(范围4.1至10.5年)。
眼眶肌炎对口服皮质类固醇反应良好,但50%的病例会复发。基于对6例接受20 Gy放疗患者的长期随访,放疗似乎无法有效阻止复发性眼眶肌炎。